Document is current
Any future updates will be listed below
-
Authors
Kuhn, Manuel http://orcid.org/0000-0003-1483-1318
Clarenbach, Christian F. http://orcid.org/0000-0003-2158-2321
Kläy, Adrian
Kohler, Malcolm
Mayer, Laura C.
Lüchinger, Martin
Andrist, Belinda
Radtke, Thomas http://orcid.org/0000-0002-1723-1070
Haile, Sarah R. http://orcid.org/0000-0002-4704-6570
Sievi, Noriane A. http://orcid.org/0000-0003-1758-4586
Kohlbrenner, Dario http://orcid.org/0000-0001-6674-5193
-
Funding
Funding for this research was provided by:
Heubergstiftung (09-2022)
Lunge Zürich (03-2021, 03-2021)
- License Information
-
More Information
Article History
Received: 24 May 2024
Accepted: 19 July 2024
First Online: 15 August 2024
Declarations
:
: The study was conducted in accordance with the Declaration of Helsinki, and all subjects provided written informed consent. The Ethics Committee of the Canton of Zurich approved the study (2021–02038). The study is registered on clinicaltrials.gov (NCT05163600). All methods were carried out in accordance with relevant guidelines and regulations.
: Not applicable.
: N. A. Sievi, D. Kohlbrenner., A. Kläy, M. Lüchinger, B. Andrist, T. Radtke, S. R. Haile, L.C. Mayer and M. Kuhn have no conflicts of interest. C. F. Clarenbach received advisory fees from Roche, Novartis, Boehringer, GSK, Astra Zeneca, Sanofi, Vifor, OM Pharma, CSL Behring, Grifols, Daiichi Sankyo and MSD within the last 36 months. M. Kohler is a board member of Deep Breath Intelligence AG, a company that provides services in the field of breath analysis and reports consulting fees from Novartis and GSK. The results of the study are presented clearly, honestly, and without fabrication, falsification, or inappropriate data manipulation.
